Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial February 16, 2023May 23, 2023
Alterity’s lead drug candidate receives positive opinion from European medical agency November 18, 2019August 16, 2022